ShareHope Medicine Co Ltd

ShareHope Medicine Co Ltd maintains a debt-to-equity ratio of 0.58, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium risk, with a current ratio of 1.71, suggesting it can cover its short-term liabilities with its short-term assets, but with limited excess. However, the company's cash and equivalents of 50.82 million TWD are significantly lower than its long-term debt of 2.07 billion TWD, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, ShareHope Medicine Co Ltd reports a return on equity (ROE) of 0.69% and a return on assets (ROA) of 0.33%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's operating income of 22.81 million TWD and net income of 24.53 million TWD reflect a narrow margin, which may limit its ability to reinvest in growth or withstand market volatility.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates or if regulatory changes impact its operations.

Looking ahead, the company's revenue outlook is constrained by its current financial performance. The most recent actual revenue of 3.06 billion TWD suggests a relatively stable but modest growth trajectory, with no significant acceleration in the near term. The company's capital expenditures of -28.15 million TWD indicate a reduction in investment in physical assets, which may signal a strategic shift or financial prudence.

The risk assessment highlights liquidity as a medium concern, with the company's cash reserves insufficient to cover its long-term obligations. The dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares, suggesting no imminent threat from share issuance. However, the company's net cash position remains a concern, as it is significantly negative after accounting for total debt.

Recent events, as reflected in the financial data, show a stable but modest performance in the most recent reporting period. The company's operating cash flow of 35.65 million TWD and free cash flow of 49.91 million TWD indicate a positive cash generation capability, but the magnitude is relatively small given the company's asset base. No specific filings or transcripts are available to provide further insight into recent strategic or operational developments.

ShareHope's cash conversion ratio of 1.45 exceeds the pharmaceutical cohort median of 0.95, indicating superior cash generation efficiency.

The company maintains a debt-to-equity ratio of 0.58, which is below the cohort median of 0.18, suggesting a conservative leverage profile.

Long-term debt decreased to TWD 1.79 billion in 2019 from TWD 2.02 billion in 2016, showing a trend of debt reduction.

Revenue remained relatively stable, growing slightly from TWD 3.85 billion in FY-4 to TWD 4.36 billion in FY0.

The company faces high credit risk according to risk flags, indicating potential difficulties in meeting financial obligations.

Revenue TWD 1.13B, +1,3% YoY; Operating income +21,1% YoY.

• ▍Revenue TWD 1.13B, +1,3% YoY
• ▍Operating income +21,1% YoY
• ▍Net income −41,0% YoY
• ▍Free cash flow −22,4% YoY
• ▍Net margin 4.6%

Revenue TWD 1.11B, −3,7% YoY; Operating income +141,3% YoY.

• ▍Revenue TWD 1.11B, −3,7% YoY
• ▍Operating income +141,3% YoY
• ▍Net income +85,3% YoY
• ▍Free cash flow +38,5% YoY
• ▍Net margin 2.8%

Revenue TWD 1.07B, −1,7% YoY; Operating income −38,7% YoY.

• ▍Revenue TWD 1.07B, −1,7% YoY
• ▍Operating income −38,7% YoY
• ▍Net income −60,8% YoY
• ▍Free cash flow −80,7% YoY
• ▍Net margin 2.6%

Revenue TWD 1.05B, +8,1% YoY; Operating income +33,7% YoY.

• ▍Revenue TWD 1.05B, +8,1% YoY
• ▍Operating income +33,7% YoY
• ▍Net income +26,5% YoY
• ▍Free cash flow −8,8% YoY
• ▍Net margin 3.0%

Revenue TWD 1.11B; Operating income TWD 58.3M.

• ▍Revenue TWD 1.11B
• ▍Operating income TWD 58.3M
• ▍Net margin 7.9%

Revenue TWD 1.15B; Operating income TWD 19.8M.

• ▍Revenue TWD 1.15B
• ▍Operating income TWD 19.8M
• ▍Net margin 1.5%

Revenue TWD 1.09B; Operating income TWD 35.9M.

• ▍Revenue TWD 1.09B
• ▍Operating income TWD 35.9M
• ▍Net margin 6.5%

Revenue TWD 4.36B, +0,7% YoY; Operating income +24,9% YoY.

• ▍Revenue TWD 4.36B, +0,7% YoY
• ▍Operating income +24,9% YoY
• ▍Net income −29,2% YoY
• ▍Free cash flow −46,1% YoY
• ▍Net margin 3.3%

Revenue TWD 4.33B, +11,7% YoY; Operating income +14,0% YoY.

• ▍Revenue TWD 4.33B, +11,7% YoY
• ▍Operating income +14,0% YoY
• ▍Net income +60,6% YoY
• ▍Free cash flow +8 973,3% YoY
• ▍Net margin 4.6%

Revenue TWD 4.14B, +7,5% YoY; Operating income +23,6% YoY.

• ▍Revenue TWD 4.14B, +7,5% YoY
• ▍Operating income +23,6% YoY
• ▍Net income +26,3% YoY
• ▍Free cash flow −513,8% YoY
• ▍Net margin 7.1%